Twitter Linkedin Envelope
REQUEST A CALL

Kenyetta Sims Announced as Director of Diversity Training & Education of Total Diversity Clinical Trial Management

Press Releases

/

March 15, 2022

March 15, 2022 – Total Diversity Clinical Trial Management, a global Contract Research Organization and full-service Diversity Organization, has announced Kenyetta Sims, MAOM, CCRC as the Director of Diversity Training & Education.

Kenyetta is an innovative leader who has successfully worked with underrepresented populations for two decades in community-based healthcare and one decade in the Federally Qualified Health Center (FQHC) setting. This setting provides primary care services to underserved areas through federally funded community-based healthcare providers. Focusing on the elimination of health disparities in research, Kenyetta is experienced in the conduct of nationally funded research addressing gaps in LGBTQ+ health, HIV/AIDS treatment & prevention and other infectious diseases involving gender affirming care.

Kenyetta brings with her first-hand knowledge of barriers to study participation, as well as the solutions needed at the site level to improve diverse patient access to clinical trials. Leveraging these insights alongside her expertise in curriculum and program development, Kenyetta has developed Total Diversity’s diversity training and education program (DTEACHTM), which targets research site’s individual needs related to the recruitment and enrollment of diverse patient populations in clinical trials.

“Kenyetta’s role with Total Diversity is timely as many clients are turning to us to learn how to train their sites and site networks”, said Kim Kundert, SVP of Site Development Services at Total Diversity.

About TOTAL Diversity Clinical Trial Management

TOTAL Diversity Clinical Trial Management is a full-service CRO and Diversity Organization with an integrated focus on support services highlighting diversity and inclusion in clinical trials. Service offerings directed at diversity include consulting, feasibility assessment for sites, training programs, patient recruitment and retention services and more. Our established network of sites includes experienced diversity-oriented researchers as well as those who have access to diverse populations.

REQUEST A CALL

Diana L. Foster, Ph.D

CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management

Diana L. Foster, Ph.D., is the CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management, a full-service Diversity Organization whose mission is to enhance diversity and inclusion in clinical research trials. Foster has served as the Vice President of Diversity, Equity, and Inclusion for the Society of Clinical Research Sites (SCRS) since 2016. She also held a position as the Vice President of Strategy and Development for SCRS originating programs such as the Global Impact Partner Programs and many other industry supported initiatives.

Foster is a thought-leader and sought-after expert in diversity and clinical site best practices. She is the author of the Diversity Site Assessment Tool and has published numerous research papers on the topic. Over the past two decades, she has addressed audiences across the world, published multiple papers and articles, and written five authoritative industry books including Global Issues in Patient Recruitment and Retention.

Jerome Adams, M.D.

Chairman of the Board for TOTAL Diversity Clinical Trial Management

Dr. Adams also currently serves as Executive Director of Health Equity Initiatives at Purdue University. He formerly served as the 20th United States Surgeon General and as a member of the President’s COVID-19 task force, where he was at the forefront of America’s most pressing health challenges throughout the pandemic, including working with companies to increase diversity in vaccine trials.

As the Chairman of the Board for TOTAL Diversity, Dr. Adams provides his in-depth knowledge of patient perspectives and industry views on diversity to create sustainable solutions and best practices to establish more diverse representation in clinical trials.